Riot Platforms has finalized the transfer of its Bitcoin custody from NYDIG Trust Company to BitGo Bank & Trust, ending a custody agreement that began in November 2023. The transition involved no early termination penalties and introduced a new agreement with segregated accounts and early exit options. Riot sold over 20,000 BTC in 2026 to fund its expanding data center operations, ending September with 2,418 BTC valued at $202 million. This move aligns with Riot's broader strategy to grow its data center capacity, now contracted at 1,151 megawatts, and reflects ongoing changes in its Bitcoin holdings and financing arrangements.
Riot Platforms' Bitcoin custody transfer is presented here with Pluang's cryptocurrency market data as context. For readers following major cryptocurrencies, 30 out of 50 rose while 19 fell as of Nov 04, 2026 21:23 WIB. Notable price changes include Basic Attention Token (BAT) up 9.25% at Rp2.507 and EOS (EOS.IO) up 8.13% at Rp12.649.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
